Resumen
La quimioterapia a altas dosis con soporte autólogo de médula ósea o de progenitores periféricos es una modalidad terapéutica utilizada frecuentemente en el tratamiento de consolidación de los niños con neoplasias sólidas quimiosensibles de alto riesgo. El incremento en su utilización ha permitido refinar este tratamiento disminuyendo considerablemente la morbimortalidad asociada a este procedimiento. Se ha demostrado su efectividad en el neuroblastoma de alto riesgo y en los tumores germinales recidivados o refractarios. Existen asimismo suficientes evidencias de que en el sarcoma de Ewing de alto riesgo y en algunos tumores cerebrales recidivados o metastásicos la utilización de esta estrategia contribuye de modo significativo a la mejoría del pronóstico.
Abstract
High-dose chemotherapy with autologous bone marrow or peripheral stem cell support is frequently used for the treatment of high-risk pediatric solid tumors. The gained experience with these treatments runs parallel with a considerable decrease on the procedure-related complications. These strategies have demonstrated its efectivity in the treatment of high-risk neuroblastoma as well as in refractory or relapsed germ cell tumors. There are also evidences showing that its use in high-risk Ewing’s sarcoma, and in chemosensitive relapsed or metastatatic brain tumors, contributes to ameliorate the dismal prognosis of these patients.
Article PDF
Avoid common mistakes on your manuscript.
Bibliografía
Seeger R, Reynolds C. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 1991; 38: 393–424.
Herzig R, Lazarus H, Graham-Pole J, et al. Autologous bone marrow transplantation for malignant diseases: a phase I–II study for melanoma, neuroblastoma, Ewing’s sarcoma, and germ cell tumors using high-dose melphalan. En: Gale RP, ed. Recent advances in bone marrow transplantatation. New York: Liss, 1983; 643–657.
Sánchez de Toledo J, Gallego S, Pérez Payarols J, et al. Melfalán a altas dosis seguido de autotrasplante de médula ósea en tumores sólidos de la infancia. Med Clin 1989; 86: 621–623.
Ozkaynak M, Matthay K, Cairo M, et al. Double-alkilator non-total-body irradiation regimen with autologous hematopietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol 1998; 16: 937–944.
Kajiume T, Kawano Y, Takaue Y, et al. New consecutive high-dose chemotherapy modality with fractionated blood stem cell support in the treatment of high-risk pediatric solid tumors: a feasibility study. Bone Marrow Transplant 1998; 21: 147–151.
Gratwohl A, Passweg J, Baldomero H, et al. Blood and bone marrow transplantation activity in Europe 1996. Bone Marrow Transplant 1998; 22: 227–240.
Goldman JM, Schmitz N, Niethammer D, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Bone Marrow Transplant 1998; 21: 1–7.
Brodeur G, Maris J, Yamashiro D, et al. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997; 19: 93–101.
Stram D, Matthay K, O’Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children’s Cancer Group studies. J Clin Oncol 1996; 14: 2.417–2.426.
Matthay K, Villablanca J, Seeger R, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic. N Engl J Med 1999; 341: 1.165–1.173.
Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953–965.
Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single Institution. Bone Marrow Transplant 1999; 23: 789–795.
Sandoval C, Meyer W, Parham D, et al. Outcome in 43 children presenting with metastatic Ewing’s sarcoma: the St Jude Children’s Research Hospital experience, 1962–1992. Med Ped Oncol 1996; 26: 180–185.
Burdach S, Jurgen H, Peters C, et al. Myeloablative radiochemotherapy and hemopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 1993; 11: 1.482–1.488.
Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697–705.
Ladenstein R, Hartmann O, Pinkerton R, et al. A multivariate and matched pair analysis on high-risk Ewing tumor patients undergoing MGT/SCR in Europe. Bone Marrow Transplant 1997; 20: S227.
Díaz M, Vicent M, Madero L. High-dose busulphan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1.157–1.159.
Madero L, Muñoz A, Sánchez de Toledo J, et al. Megatherapy in children with high-risk Ewing’s sarcoma in first complete remission. Bone Marrow Transplant 1998; 21: 795–799.
Atra A, Whelan J, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing’s sarcoma. Bone Marrow Transplant 1997; 20: 843–846.
Paulussen M, Braun-Munzinger G, Burdach S, et al. Treatment results in Ewing’s sarcoma with pulmonary metastases at diagnosis: a retrospective analysis of 41 patients. Klin Pädiatr 1993; 205: 210–216.
Mason W, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16: 210–221.
Kalifa C, Hartmann O, Vassal G, et al. High-dose busulphan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992; 9: 227–233.
Valteau-Couanet D, Kalifa C, Benhamou E, et al. Repeated high-dose chemotherapy followed by stem cell transplantation in young children with poor prognosis medulloblastoma or PNET: tolerance and efficacy. Bone Marrow Transplant 1997; 20: S228.
Dunkel I, Bayett J, Rosenblum M, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998; 16: 222–228.
Mahoney D, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study. J Clin Oncol 1996; 14: 382–388.
Graham M, Herndon J, Casey J, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15: 1.814–1.823.
Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2.638–2.645.
Rick O, Beyer N, Schwella D, et al. Long-term survival after high-dose salvage chemotherapy in patients with germ cell tumors. Bone Marrow Transplant 1997; 20: S228.
Margolin K, Doroshow J, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem cell support. J Clin Oncol 1996; 14: 2.631–2.637.
Motzer R, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1.173–1.780.
Koscielniak E, Rosti G, Treuner J, et al. Prognosis in patients with primary bone and/or bone marrow metastases of rhabdomyosarcoma. A joint report of the EBMT solid tumor working party and the German Soft Tissue Sarcoma Study. Bone Marrow Transplant 1997; 20: S226.
Boulad F, Kernan N, LaQuaglia M, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16: 1.697–1.706.
Schwella N, Rick O, Meyer O, et al. Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcomas. Bone Marrow Transplant 1998; 21: 863–868.
D’Angio G, Breslow N, Beckwith J, et al. Treatment of Wilms’tumor. Results of the Third National Wilms’ Tumor Study. Cancer 1989; 64: 349–360.
Grundy P, Breslow N, Green D, et al. Prognostic factors for children with recurrent Wilms’ tumor: results for the Second and Third National Wilms’ Tumor Study. J Clin Oncol 1989; 7: 638–647.
Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: A French Society of Pediatric Oncology Study. J Clin Oncol 1998; 16: 3.295–3.301.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melcón, S.G., de Toledo Codina, J.S. Quimioterapia intensiva con soporte de progenitores hematopoyéticos en neoplasias sólidas no hematológicas de la edad pediátrica: indicaciones y estado actual del tema. Rev Oncol 3, 5–10 (2001). https://doi.org/10.1007/BF02711766
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02711766
Palabras clave
- neuroblastoma
- sarcoma de Ewing
- tumores cerebrales
- tumores germinales
- rabdomiosarcoma
- tumor de Wilms
- progenitores hematopoyéticos
- quimioterapia a altas dosis